Efficacy of Anti-Amyloid Therapies in Alzheimer’s Disease

Porszász, RóbertShim, Yubin2025-07-022025-07-022025-05-12https://hdl.handle.net/2437/395329Alzheimer’s disease (AD) is the most common form of dementia, driven by amyloid-β (Aβ) and tau pathology. Anti-Aβ monoclonal antibodies (mAbs) like aducanumab, lecanemab, and donanemab aim to slow progression by promoting microglial clearance of Aβ plaques. These therapies have shown modest clinical benefits in early-stage AD, but risks such as amyloid-related imaging abnormalities (ARIA), especially in APOE4 carriers, remain a concern. While not curative, mAbs represent a significant advancement in disease-modifying treatment. Ongoing trials continue to assess long-term efficacy, safety, and patient selection strategies.39 pagesenAlzheimer’s disease (AD)Efficacy of Anti-Amyloid Therapies in Alzheimer’s DiseaseA Critical Review of Clinical TrialsMedicine::PharmacologyHozzáférhető a 2022 decemberi felsőoktatási törvénymódosítás értelmében.